Navigation Links
Erbitux in Medical News
Unmet Need for Efficacious Therapies for Treating Patients With Mutated KRAS Genes Presents Significant Opportunity for Drug Developers, According to a New Report from Decision Resources
WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advis...
Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issue...
...rolong overall survival. Almost 5,000 NSCLC Patients Monitored Merck KGaA already had presented at last year's ASCO a landmark study for erbitux in combination with standard 1st-line chemotherapy in advanced NSCLC which showed for the first time in 10 years a significant survival benefit in a b...
... Roche/Chugai's Avastin (bevacizumab) and Merck KGaA/Bristol-Myers Squibb's erbitux (cetuximab) despite their high cost. Growth of these agents and the launch ...illion in 2013. "The increased use of targeted agents like Avastin and erbitux is due to the increasing wealth and urbanization among India's population a...
Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issue...
A New Erbitux Combo Shows Promise in treatment
The US-based ImClone Systems and Bristol-Myers Squibb have announced that a first line phase III study of Erbitux combined with platinum-based //chemotherapy have increased survival chances among cancer patients with recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN). ...Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
...e of 54 percent, primarily due to the inclusion of erbitux revenue as a result of the ImClone acquisition. U....ion of Byetta revenue and $99.7 million of erbitux revenue. Zyprexa In the sec...tta outside the U.S. were $30.6 million. erbitux ((R)) Lilly reports in collaboration revenue......rolong overall survival. Almost 5,000 NSCLC Patients Monitored Merck KGaA already had presented at last year's ASCO a landmark study for erbitux in combination with standard 1st-line chemotherapy in advanced NSCLC which showed for the first time in 10 years a significant survival benefit in a b...
Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
...eva (erlotinib) and Jiangsu Simcere's Endostar (endostatin) and the launch of new targeted therapies -- Roche's Avastin (bevacizumab) and Merck KGaA's erbitux (cetuximab) -- are the main driving forces in the Chinese non-small-cell lung cancer market from 2008 to 2013. "In 2008, sales of non-small-cell ...... Roche/Chugai's Avastin (bevacizumab) and Merck KGaA/Bristol-Myers Squibb's erbitux (cetuximab) despite their high cost. Growth of these agents and the launch ...illion in 2013. "The increased use of targeted agents like Avastin and erbitux is due to the increasing wealth and urbanization among India's population a...
Lilly Reports Strong First-Quarter 2009 Results
...e of 58 percent, primarily due to the inclusion of erbitux revenue as a result of the ImClone acquisition. U.... Byetta outside the U.S. were $23.7 million. erbitux Lilly reports in collaboration revenue the net royalties received from its erbitux collaboration partners, and in product sales the r...Targeted Treatments Show Mettle Against Advanced Cancers
...at specific genetic mutations in patients with advanced colorectal cancer could indicate that the tumor will not respond to two monoclonal antibodies, erbitux (cetuximab) and Vectibix (panitumumab). Two studies also to be presented at the meeting focused on the brain tumors known as glioblastomas. One ...Chinese Colorectal Cancer Drug Market Will More Than Double by 2012
...nt cases, improvement in access to medical care and significantly increased prescribing of targeted therapies. "The increased use of Merck KGaA's erbitux and Jiangsu Simcere's Endostar and the launch of Roche's Avastin will be the strongest drivers of the Chinese colorectal drug market during the next f...Erbitux in Medical Technology
Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix
DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treat...
- ViziLite Plus with TBlue630 - PHOENIX, Sept. 4 /PRNewswire-FirstCall/ -- Zila, Inc.'s (Nasdaq: ZILA ) ViziLite(R) Plus with Tblue630(TM) screening system for early detection of abnormalities which can lead to oral cancer, has been selected to identify pre-cancerous lesio...
- As previously announced, primary endpoint not met; plausibly confounded by survival benefit of post-study treatment with ERBITUX - NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced detailed results from the EPIC study...
...rior FOLFOX (Oxaliplatin + 5FU + Leucovorin); 63% were previously treated with both FOLFIRI and FOLFOX; 77% received prior Avastin (R) ; and 43% prior erbitux (R) . Prior treatment with single agent capecitabine was excluded. The primary endpoints of this study were to measure 1) Time to Progression (T...
- ViziLite Plus with TBlue630 - PHOENIX, Sept. 4 /PRNewswire-FirstCall/ -- Zila, Inc.'s (Nasdaq: ZILA ) ViziLite(R) Plus with Tblue630(TM) screening system for early detection of abnormalities which can lead to oral cancer, has been selected to identify pre-cancerous lesio...
Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that a first line Phase III study of ERBITUX(R) (Cetuximab) combined with platinum-based chemotherapy met the primary endpoint of increasing overall surv...Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
-- First large, randomized Phase III study of ERBITUX with chemotherapy in recurrent and/or metastatic head and neck cancer meets primary endpoint of improving overall survival -- NEW YORK, April 04, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company annou...Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not...- As previously announced, primary endpoint not met; plausibly confounded by survival benefit of post-study treatment with ERBITUX - NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced detailed results from the EPIC study...
Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
NEW YORK--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (cetuximab), the first approved IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR) developed and commercialized by ImClone Systems Incorporated, was the focus of nine oral and 46 poster presentations at the recently conclu...Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced results from an open-label Phase III study of ERBITUX(R) (Cetuximab) plus a taxane and carboplatin in the first-line treatment for metastatic non-small cell lung cancer (...ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
...elopment, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benef......rior FOLFOX (Oxaliplatin + 5FU + Leucovorin); 63% were previously treated with both FOLFIRI and FOLFOX; 77% received prior Avastin (R) ; and 43% prior erbitux (R) . Prior treatment with single agent capecitabine was excluded. The primary endpoints of this study were to measure 1) Time to Progression (T...
Erbitux in Biological News
Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
...atment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of erbitux for metastatic colorectal cancer. Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostic...Two designer drugs hit same lung cancer target, but only one is effective
...er drugs critically influence their effectiveness. erbitux is an effective inhibitor of EGFR signals in color..., MD, and Jänne, all of Dana-Farber. Iressa and erbitux both are designed to squelch the overexpressed, or...ara and his colleagues wanted to determine whether erbitux might be another option for NSCLC patients who car...FDA Works To Speed The Advent Of New, More Effective Personalized Medicines
...his technology has enabled the development of targeted therapies like Herceptin for metastatic breast cancer, Gleevec for chronic myeloid leukemia and erbitux for metastatic colorectal cancer. "FDA's efforts will bring us one step closer to 'personalizing' medical treatment," explained Janet Woodcock, M.D...Erbitux in Biological Technology
... for Erbitux, as well as the
later-stage oncology compounds currently in development.
-- ERBITUX(R) - In addition to its approved indications, erbitux is also
being studied in numerous cancer types, including colorectal, head and neck,
non-small cell lung, gastric and esophageal.
-- IMC-1121B...
...evenue) 273 226 21% 175 144 22% 15% Baraclude 108 45 140% 29 17 71% 59% Oncology erbitux 187 160 17% 185 158 17% N/A Taxol 94 111 (15)% - 4 (100)% N/A Sprycel ...
...s that would persuade them to add ImClone/Bristol-Myers Squibb/Merck KGaA's erbitux to Genentech/Roche's Avastin and chemotherapy for first-line treatment of a...would require a significant improvement in overall survival in order to add erbitux to Avastin and chemotherapy. On average, oncologists require 24 percent imp...
Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
...al in moving forward the clinical development program for ERBITUX(R) (cetuximab), an oncology drug now approved in colorectal and head & neck cancers. erbitux (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor...Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
...eater advancements in our proprietary pipeline." erbitux is marketed by ImClone's two partners, Merck KGaA ...istol- Myers Squibb (BMS), and ImClone co-promotes erbitux in North America together with BMS. erbitux is indicated as both a single agent and with chemo...Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
...atment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of erbitux for metastatic colorectal cancer. Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostic...ASCO Results: Oncologists Rank Genentech Number One
...ces of data presented at ASCO: -- KRAS status predicts response to first-line cetuximab for metastatic colorectal cancer. -- erbitux (cetuximab) + platinum-based chemotherapy extends overall survival in NSCLC vs. chemotherapy alone. -- Zometa (zoledronic acid) increas......evenue) 273 226 21% 175 144 22% 15% Baraclude 108 45 140% 29 17 71% 59% Oncology erbitux 187 160 17% 185 158 17% N/A Taxol 94 111 (15)% - 4 (100)% N/A Sprycel ...
...s that would persuade them to add ImClone/Bristol-Myers Squibb/Merck KGaA's erbitux to Genentech/Roche's Avastin and chemotherapy for first-line treatment of a...would require a significant improvement in overall survival in order to add erbitux to Avastin and chemotherapy. On average, oncologists require 24 percent imp...
Biotech 2004: Cautious optimism
... the last two weeks has approved not one but two new cancer drugs coming from biotech companies: Genentechs Avastin and the controversial ImClones erbitux (remember that this is the product and company that did in Marsha Stewart). 2. The hostile announced takeover of the French-German giant Aventis b...Other TagsOther Contents
(Date:5/21/2013)... The monstrous tornado that devastated Moore, Okla., on ... a stunning example of violent weather that can ... thunderstorms with lightning and strong winds can be ... Some anxiety in the face of violent weather ... that interfere with their everyday lives, said Stephen ...
(Date:5/21/2013)... Philosophical Society (APS) has awarded New York University neuroscientist ... in recognition of his "pioneering work on the neuroscience ... University,s Center for Neural Science, is the second NYU ... yearsJoseph LeDoux received the honor in 2011 in recognition ... emotional learning, particularly fear learning, and fear memory." ...
(Date:5/21/2013)... Residents in St. Petersburg, FL have ... that Dr. David Sherberg, DMD, has joined Coast Dental ... Sherberg provides preventive, restorative and cosmetic dentistry to patients ... team provide a wide variety of services ... therapy, crowns, bridges, dentures, dental implant restorations, veneers, laser ...
(Date:5/21/2013)... Benefit Express Services, LLC, a leader in providing ... be hosting a free Workplace Wellness webinar on June ... presentation will focus on making sure your workplace wellness ... Care Reform Requirements. The team will also share some ... regularly hosts free educational webinars on issues that today's ...
(Date:5/21/2013)... hear the sound of galloping hooves behind you, your immediate ... cases it is actually a zebra approaching. Doctors are trained ... in their practices, and as they rarely or never meet ... often takes many years to reach the right diagnosis. A ... in many cases. , Ole Winther is Associate Professor ...
Breaking Medicine News(10 mins):Health News:Weather Worries Can Threaten a Child's Mental Health 2Health News:NYU's Movshon receives Lashley Award for his research on the neuroscience of vision 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3Health News:Benefit Express to Host Workplace Wellness Webinar 2Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/18/2013)... (May 18, 2013) An increasing number of ... interventions to resolve, according to research presented at ... study targeting obesity, researchers at the Cleveland Clinic ... unique pattern of exhaled breath compared to their ... organic compound levels that can be correlated to ...
(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |